Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis - Nature Reviews Neurology
Source : https://www.nature.com/articles/s41582-021-00581-x
Despite substantial progress in the development of disease-modifying therapies for multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) remain limited. The authors present criteria for therapeutic success in...
Key points:
- Prominent pathological features of progressive multiple sclerosis (PMS) include global brain atrophy, slowly expanding lesions and a predominantly microglia/macrophage-mediated inflammatory response.
- Neurodegeneration in MS seems to be driven by a complex interplay between compartmentalized neuroinflammation, oxidative stress,...
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
Source : https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.1c00926
Multiple Sclerosis is a chronic autoimmune neurodegenerative disorder of the central nervous system (CNS) that is characterized by inflammation, demyelination, and axonal injury leading to permeant disability. In the early...
Herein, we describe the discovery of BIIB091, a structurally distinct orthosteric ATP competitive, reversible inhibitor that binds the BTK protein in a DFG-in confirmation designed to sequester Tyr-551, an important phosphorylation site on BTK, into an inactive conformation with excellent affinity. Preclinical studies demonstrated BIB091 to be...
Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study - BMC Health Services Research
Source : https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-021-07012-z
Background Besides coping with a disease with many uncertainties, people with relapsing-remitting multiple sclerosis face complex decisions concerning disease-modifying therapies (DMTs). In an interview study, we aimed to assess patients'...
Conclusions: The study provides a rich and nuanced amount of patients’ experiences with DMTs. The findings demonstrate the importance for practitioners to look at current life circumstances of patients with multiple sclerosis when recommending a DMT and to promote and enable patients to make informed decisions.
-
MS Connect4yrKey Points • Source: BMC Health Services Research • Conclusion/Relevance: “The study provides a rich and nuanced amount of patients’ experiences with DMTs. The findings demonstrate the importance for practitioners to look Show More
Contribution of Metabolomics to Multiple Sclerosis Diagnosis, Prognosis and Treatment
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541167/
Alexey Boyko, Academic Editor Metabolomics-based technologies map in vivo biochemical changes that may be used as early indicators of pathological abnormalities prior to the development of clinical symptoms in neurological...
In this review, we offer evidence in support of metabolites that are described as potential biomarkers in the literature of MS biofluids upstream regulators, and show novel, still unexplored metabolic pathways, whose investigation may open novel avenues of research.
Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34720605/
1 Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA. 2 Autoimmunity Center of Excellence, University of Michigan Medical School, Ann Arbor, MI, USA. 3 Graduate Program...
Conclusions: These differences may facilitate personalized precision medicine and aid in the discovery of new therapeutic targets for disease progression through the improvement of patient stratification.